Synfacts 2020; 16(12): 1385
DOI: 10.1055/s-0040-1706387
Synthesis of Natural Products and Potential Drugs

Synthesis of Olodanrigan

Philip Kocienski
Hargdegger LA. * et al. Novartis Pharma, Basel, Switzerland
Toward a Scalable Synthesis and Process for EMA401, Part I: Late Stage Process Development, Route Scouting, and ICH M7 Assessment.

Org. Process Res. Dev. 2020;
24: 1743-1755
DOI: 10.1021/acs.oprd.0c00215.


Olodanrigan (EMA401) is an angiotensin II type 2 antagonist that had been considered for the treatment of postherpetic neuralgia and neuropathic pain. This short synthesis of olodanrigan is presented in detail in three back-to-back papers. Part 1 concerns the optimized conversion of the phenylalanine C to the target molecule and includes the search for a suitable polymorph. Part 2 (Org. Process Res. Dev. 2020, 24, 1756) concerns development of a pyridine- and piperidine-free Knoevenagel–Doebner condensation using a catalytic amount of morpholine that delivered 25 kg of cinnamic acid C in 98% yield.



Part 3 (Org. Process Res. Dev. 2020, 24, 1763) describes the hydroamination of the cinnamic acid B using an engineered phenylalanine ammonia lyase enzyme to afford amino acid C. Enzyme loadings as low as 2.5 wt% (E/S = 1:40 w/w) and substrate concentrations between 1.17–0.39 M were compatible with the reaction conditions. The telescoped process from B via C to tetrahydroisoquinoline D was scaled up to a batch size of 2 kg, resulting in 81% conversion to C and a 59% isolated yield of D with high chiral purity (er = 99.9:0.1).



17. November 2020 (online)

© 2020. Thieme. All rights reserved

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany